# miDiagnostics NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/midiagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Leuven, Belgium
- Website: www.midiagnostics.com
- Total disclosed funding: $17M
- Latest round: Series D (Dec 27, 2024)
- Investors on record: 4

## About

Based in Belgium, miDiagnostics NV develops advanced diagnostic testing solutions utilizing proprietary silicon chip technology for efficient point-of-care testing.Founded in 2015 and headquartered in Leuven, Belgium, miDiagnostics NV focuses on developing diagnostic testing solutions. The firm has completed four significant deals, with its most recent funding round occurring on December 4, 2024. The company raised EUR 30.00 mn in Series D funding, led by Thermo Fisher Scientific Inc., and participated in by Alychlo, Pamica, and VMF Invest. Katleen Verleysen serves as CEO, guiding the company through its growth trajectory.miDiagnostics primarily specializes in advanced diagnostic testing solutions powered by proprietary silicon chip technology. The core product offering includes a highly precise and cost-effective test-card designed for rapid point-of-care testing. This innovative product facilitates ultrafast PCR (polymerase chain reaction) testing, enabling healthcare professionals to deliver diagnostic information efficiently to both clinicians and patients. The end use cases target critical healthcare settings, including nursing homes and home care environments, where timely intervention is essential for managing outbreaks. miDiagnostics serves a diverse clientele that includes healthcare providers, hospitals, and bio-pharma companies, with its products being utilized in various international markets across Europe and the United States.miDiagnostics generates revenue through the sale of its specialized diagnostic test-cards, which are employed in clinical and point-of-care testing scenarios. The company engages in direct sales to healthcare institutions and partners with bio-pharma firms, creating a business model that combines B2B transactions with direct-to-consumer engagements. In the year 2022, the company reported revenues of EUR 266,311.80 and an EBITDA of EUR -10,516,868.70. The flagship offering, the test-card, is central to the company’s revenue stream, reflecting its commitment to transforming the diagnostics landscape through rapid and accurate testing solutions.In December 2024, miDiagnostics NV raised EUR 30.00 mn in Series D funding, to accelerate the development of a sterility test for batch release and related quality control tests for the biopharma industry, leveraging its proprietary qPCR technology. The company aims to expand its product offerings and strategically target new markets for its diagnostic solutions, enhancing its presence in the biopharma sector.

## Funding rounds

- Series D, Dec 27, 2024, $17M — Thermo Fisher Scientific Inc., Pamica, Alychlo, VMF Invest

## Investors

- Thermo Fisher Scientific Inc. — Series D
- Pamica (https://capitalatlas.ai/funds/pamica) — Series D
- Alychlo (https://capitalatlas.ai/funds/alychlo) — Series D
- VMF Invest — Series D